Stock Events

Stock Events

Firebrick Pharma 

A$0.027000
4
-A$0.00-12.9%Wednesday 22:59

Statistics

Day High
0.027
Day Low
0.027
52W High
0.074
52W Low
0.024
Volume
3,674
Avg. Volume
150,754
Mkt Cap
7.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Nov 15Expected
Q4 2021
Q2 2022
Q3 2024
-0.04
-0.03
-0.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-2,889.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
106,000Revenue
-3.06MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FRE.AU. It's not an investment recommendation.
ASX
2
ASX.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline, a large pharmaceutical company, develops respiratory products and vaccines, competing in similar markets as Firebrick Pharma.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca is involved in the development of respiratory drugs and treatments for infections, directly competing with Firebrick Pharma's nasal spray for cold prevention.
Pfizer
PFE
Mkt Cap158.45B
Pfizer produces a wide range of medications including those for respiratory conditions, positioning it as a competitor in the same therapeutic area.
Merck
MRK
Mkt Cap356.01B
Merck & Co., known for its innovative treatments and vaccines, competes in the pharmaceutical market addressing diseases similar to those targeted by Firebrick Pharma.
Novartis
NVS
Mkt Cap268B
Novartis manufactures drugs for a variety of ailments including respiratory diseases, making it a competitor in the same field as Firebrick Pharma.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson offers products in the pharmaceutical and consumer health sectors, including treatments for respiratory conditions, competing with Firebrick Pharma.
Sanofi
SNY
Mkt Cap95.65B
Sanofi produces medications for respiratory issues and vaccines, areas that overlap with Firebrick Pharma's product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol-Myers Squibb, a global biopharmaceutical company, develops drugs that could be used in treating conditions similar to those targeted by Firebrick Pharma.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie, with its broad range of pharmaceutical products, competes in the therapeutic areas relevant to Firebrick Pharma's focus.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the research and development of pharmaceutical products for various health issues, including those addressed by Firebrick Pharma.

About

Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
Show More
CEO
Peter Laurence Molloy
Employees
6
Country
Australia
ISIN
AU0000197352

Listings

AU
AU
FRE.AU

0 Comments

Share your thoughts

FAQs

What is Firebrick Pharma stock price today?▼
The current price of FRE.AU is A$0.03 AUD — it has decreased by -12.9% in the past 24 hours. Watch Firebrick Pharma stock price performance more closely on the chart.
What is Firebrick Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Australia Exchange exchange Firebrick Pharma stocks are traded under the ticker FRE.AU.
Is Firebrick Pharma stock price growing?▼
FRE.AU stock has fallen by -10% compared to the previous week, the month change is a -3.57% fall, over the last year Firebrick Pharma has showed a -61.43% decrease.
What is Firebrick Pharma market cap?▼
Today Firebrick Pharma has the market capitalization of 7.7M
What is Firebrick Pharma revenue for the last year?▼
Firebrick Pharma revenue for the last year amounts to 106,000 AUD.
What is Firebrick Pharma net income for the last year?▼
FRE.AU net income for the last year is -3.06M AUD.
How many employees does Firebrick Pharma have?▼
As of November 1, 2026, the company has 6 employees.
In which sector is Firebrick Pharma located?▼
Firebrick Pharma operates in the Health & Wellness sector.
When did Firebrick Pharma complete a stock split?▼
Firebrick Pharma has not had any recent stock splits.
Where is Firebrick Pharma headquartered?▼
Firebrick Pharma is headquartered in Melbourne, Australia.